Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Interest Coverage Ratio (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Interest Coverage Ratio for 5 consecutive years, with 151.25 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Interest Coverage Ratio fell 38.06% year-over-year to 151.25, compared with a TTM value of 145.86 through Jun 2025, down 179.12%, and an annual FY2025 reading of 203.41, down 50.93% over the prior year.
  • Interest Coverage Ratio was 151.25 for Q2 2025 at SAB Biotherapeutics, down from 141.22 in the prior quarter.
  • Across five years, Interest Coverage Ratio topped out at 132.85 in Q4 2023 and bottomed at 191.46 in Q4 2021.
  • Average Interest Coverage Ratio over 5 years is 85.93, with a median of 91.85 recorded in 2022.
  • The sharpest move saw Interest Coverage Ratio crashed 960.35% in 2022, then skyrocketed 248.23% in 2023.
  • Year by year, Interest Coverage Ratio stood at 191.46 in 2021, then skyrocketed by 53.19% to 89.62 in 2022, then soared by 248.23% to 132.85 in 2023, then plummeted by 206.3% to 141.22 in 2024, then fell by 7.1% to 151.25 in 2025.
  • Business Quant data shows Interest Coverage Ratio for SABS at 151.25 in Q2 2025, 141.22 in Q4 2024, and 144.93 in Q3 2024.